title: Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study).
abstract: OBJECTIVE
  We analyzed the efficacy and safety of Preminent(®) [losartan (50 mg/day)/HCTZ (12.5 mg/day)] compared to CodioMD(®) [valsartan (80 mg/day)/HCTZ (6.25 mg/day)].
  
  
  METHODS
  In this study, 31 hypertensive patients after receiving 3 months of Preminent(®) (Stage A) were enrolled. We applied a changeover with switching from Preminent(®) to CodioMD(®) (Stage B). We then applied another changeover with switching from CodioMD(®) to Preminent(®) after 3 months (Stage C).
  
  
  RESULTS
  Average values of 24-h blood pressure (BP), daytime BP and nighttime BP using ambulatory BP monitoring (ABPM) significantly increased from Stage A to B [4/3 mmHg, 5/3 mmHg and 3/3 mmHg, respectively]. Average values of 24-h BP, morning BP, daytime BP, nighttime BP significantly decreased from the end of Stage B to C [-5/-5 mmHg, -4/-6 mmHg, -5/-5 mmHg and -6/-4 mmHg, respectively]. Interestingly, the serum levels of uric acid and the urinary albumin/creatinine ratio showed a significant increase after the change to CodioMD(®). Since these adverse effects did not disappear after the return to Preminent(®) at the end of Stage C, we performed an additional 3-month follow-up (extended stage). These adverse effects finally disappeared at the end of this extended stage.
  
  
  CONCLUSIONS
  Single-pill fixed-dose combination therapy using Preminent(®) showed significant 24-h BP-lowering effects and was safe when compared with CodioMD(®).
authors: Department of Cardiology, Fukuoka University School of Medicine, Japan.
authors: Yuhei
authors: Y
authors: Shiga
authors: Shin-ichiro
authors: S
authors: Miura
authors: Joji
authors: J
authors: Morii
authors: Takashi
authors: T
authors: Kuwano
authors: Ryoko
authors: R
authors: Mitsutake
authors: Yoshinari
authors: Y
authors: Uehara
authors: Asao
authors: A
authors: Inoue
authors: Keijiro
authors: K
authors: Saku
mesh_terms: D000368:Aged; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D004338:Drug Combinations; D057915:Drug Substitution / Q000009:adverse effects / Q000379:methods; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage* / Q000009:adverse effects; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D019808:Losartan / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D013777:Tetrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014633:Valine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000068756:Valsartan
chemical_list: D004338:Drug Combinations; D013777:Tetrazoles; C505809:hydrochlorothiazide, losartan drug combination; D006852:Hydrochlorothiazide; D000068756:Valsartan; D014633:Valine; D019808:Losartan